

November 22, 2024

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip code: 512529

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051
Symbol: SEQUENT

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Consolidation of Shareholding in (i) N-VET AB, Sweden (ii) Alivira Italia SRL, Italy to make N-VET AB and Alivira Italia SRL Wholly Owned Subsidiaries of the Company.

Please find attached disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, consequent to acquisition of:

- i) 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company.
- ii) 3.75% stake from Mr. Renzo Rimondi and 1.25% from Mr. Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company.

Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.

We request you to take the above on your record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**

Phillip Trott

Company Secretary & Compliance Officer

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra, India
Tel No.: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

Annexure-A

Details as required under Regulation 30 of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Acquisition of incremental stake of 3.90% in N-VET AB, a subsidiary of the Company

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Name of the Target Company:</p> <p>N-VET AB</p> <p>Details of Target Company:</p> <p>N-vet AB is located at Uppsala Science Park, 75183 Uppsala, Sweden and It is engaged in the business of trading in Animal Healthcare products.</p> <p>FY 2023-24 (SEK)</p> <p>Sales: 21,272,619.00</p> <p>EBIDTA: 1,954,139.00</p> <p>Net Profit: (2,048,488.00)</p> <p>Net Cash: (3,875,139.00)</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
3.	Industry to which the entity being acquired	Pharmaceuticals

	belongs	
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>The object of acquisition is to consolidate the Shareholding in N-vet AB.</p> <p>The Company was holding 96.10% stake in N-vet AB, and consequent to this acquisition, N-vet AB, has become a Wholly Owned Subsidiary of the Company.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No
6.	Indicative time period for completion of the acquisition;	Agreement signed on November 19, 2024 and Acquisition completed on November 22, 2024.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired	SEK 344000 (Three Lakh Forty-Four Thousand <i>Swedish Kroner</i>)
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	The Company has acquired 3.90% stake in N-vet AB, through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company.
10.		
a)	Brief background about the entity acquired in terms of products/line of business acquired	<p>Brief Background: N-vet is engaged in the business of trading in Animal Healthcare products.</p> <p>Line of Business: Pharmaceuticals</p>
b)	Date of incorporation	08-01-2001

c)	History of last 3 years turnover (Amount in Swedish Kroner (SEK))	FY 2021-22	22,439,574
		FY 2022-23	20,411,662
		FY 2023-24	21,272,619
d)	Country in which the acquired entity has presence	Sweden	

Annexure-B

Details as required under Regulation 30 of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Acquisition of incremental stake of 5.00% in Alivira Italia SRL, Italy a subsidiary of the Company

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Name of the Target Company:</p> <p>Alivira Italia SRL</p> <p>Details of Target Company:</p> <p>Alivira Italia SRL is located at Ferrara (Fe) Via Giorgio, Rizzi 12 Cap 44123, Italy and It is engaged in the business of trading of Animal Healthcare products.</p> <p>FY 2023-24 (Euro) Sales: 1,572,949 EBIDTA: 5,053 Net Profit: (2,064) Net Cash: (1,256,965)</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
3.	Industry to which the	Pharmaceuticals

	entity being acquired belongs	
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The object of acquisition is to consolidate the Shareholding in Alivira Italia SRL. The Company was holding 95% stake in Alivira Italia SRL and consequent to this acquisition, Alivira Italia SRL has become a Wholly Owned Subsidiary of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No
6.	Indicative time period for completion of the acquisition;	Agreements signed on November 21, 2024 and Acquisition completed on November 22, 2024.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired	Aggregate EUR 15000 (Fifteen Thousand Euro)
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	The Company has acquired 5.00% stake in Alivira Italia SRL through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company.
10.		
a)	Brief background about the entity acquired in terms of products/line of business acquired	Brief Background: Alivira Italia SRL is in the business of trading of Animal Healthcare products. Line of Business: Pharmaceuticals
b)	Date of incorporation	29-01-2019

c)	History of last 3 years turnover (Amount in Euro)	FY 2021-22	892,494
		FY 2022-23	1,267,735
		FY 2023-24	1,572,949
d)	Country in which the acquired entity has presence	Italy	